Spironolactone for Heart Failure with Preserved Ejection Fraction
Why the study?
Does spironolactone reduce the composite outcome of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization in patients with heart failure and a preserved ejection fraction?
Population
Patients with heart failure and a preserved ejection fraction
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Spironolactone should not be used to reduce CV events in HFpEF; confirms low-certainty evidence against benefit.
Structured PICO
Does spironolactone reduce the composite outcome of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization in patients with heart failure and a preserved ejection fraction?
P
Population
Patients with heart failure and a preserved ejection fraction
I
Intervention
Spironolactone
O
Outcome
Composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failurecomposite
Spironolactone does not significantly improve the primary composite cardiovascular outcome in patients with heart failure with preserved ejection fraction.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Pitt et al. (2014) studied this question.